ELAN ONGOING INVESTIGATION: BFA Law Reminds Elanco (NYSE:ELAN) Stockholders that Incurred Losses on their Investment to Contact Us about Ongoing Securities Fraud Investigation

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral para ...